Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results
Portfolio Pulse from
Pacira BioSciences reported record revenues of $701 million for 2024, despite a GAAP net loss of $100 million. The company achieved an adjusted EBITDA of $224 million. A conference call is scheduled for further details.
February 27, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pacira BioSciences reported record revenues of $701 million for 2024, but also a GAAP net loss of $100 million. The adjusted EBITDA was $224 million, indicating operational profitability.
The record revenue suggests strong sales performance, which is positive for the stock. However, the GAAP net loss may concern some investors. The positive adjusted EBITDA indicates operational profitability, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100